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The emergence and spread of multidrug-resistant P. aeruginosa infections is of great
concern, as very few agents are effective against strains of this species. Methanolic
extracts from the Coptidis Rhizoma (the rhizomes ofCoptis japonica var.major Satake) or
Phellodendri Cortex (the bark of Phellodendron chinense Schneider) markedly reduced
resistance to anti-pseudomonal aminoglycosides (e.g., amikacin) in multidrug-resistant
P. aeruginosa strains. Berberine, the most abundant benzylisoquinoline alkaloid in the
two extracts, reduced aminoglycoside resistance of P. aeruginosa via a mechanism that
required the MexXY multidrug efflux system; berberine also reduced aminoglycoside
MICs in Achromobacter xylosoxidans and Burkholderia cepacia, two species that
harbor intrinsic multidrug efflux systems very similar to the MexXY. Furthermore
this compound inhibited MexXY-dependent antibiotic resistance of other classes
including cephalosporins (cefepime), macrolides (erythromycin), and lincosamides
(lincomycin) demonstrated using a pseudomonad lacking the four other major Mex
pumps. Although phenylalanine-arginine beta-naphthylamide (PAβN), a well-known
efflux inhibitor, antagonized aminoglycoside in a MexXY-dependent manner, a lower
concentration of berberine was sufficient to reduce amikacin resistance of P. aeruginosa
in the presence of PAβN. Moreover, berberine enhanced the synergistic effects of
amikacin and piperacillin (and vice versa) in multidrug-resistant P. aeruginosa strains.
Thus, berberine appears to be a novel type inhibitor of the MexXY-dependent
aminoglycoside efflux in P. aeruginosa. As aminoglycosides are molecules of choice to
treat severe infections the clinical impact is potentially important.
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INTRODUCTION
Pseudomonas aeruginosa is a metabolically versatile bacterium
that can cause a wide range of severe opportunistic infections in
patients with serious underlyingmedical conditions (Gellatly and
Hancock, 2013). Infections caused by P. aeruginosa often are hard
to treat; inappropriate chemotherapy readily selects multidrug-
resistant P. aeruginosa against which very few agents are effective
(Poole, 2011; Morita et al., 2014). This so-called “antibiotic
resistance crisis” has been compounded by the lag in antibiotic
discovery and development programs in recent years, and is
jeopardizing the essential role played by antibiotics in current
medical practices (Rossolini et al., 2014). Moreover, P. aeruginosa
possesses an intrinsic resistance to many antimicrobials because
of the bacterium’s outer-membrane barrier, the presence of
multidrug eﬄux transporters, and endogenous antimicrobial
inactivation (Poole, 2011; Morita et al., 2015b). Although, anti-
pseudomonal agents (e.g., carbapenems) have been discovered
and developed, P. aeruginosa readily acquires resistance to
individual agents via chromosomal mutations and lateral gene
transfer (Poole, 2011; Morita et al., 2015b).
The resistance-nodulation-division (RND) eﬄux pumps play
a major role in multidrug resistant phenotype attributed to both
acquired and intrinsic mechanisms of resistance in P. aeruginosa
(Poole, 2011, 2013). This pathogen expresses several three-
component RND-type multidrug eﬄux systems, among which
four, MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-
OprM (OprA), are reported to be significant determinants of
multidrug resistance in lab and clinical isolates (Poole, 2013; Li
et al., 2015). Unlike MexAB-OprM and MexXY-OprM, which
contribute to intrinsic resistance, the MexEF-OprN andMexCD-
OprJ systems are typically quiescent in wild-type cells (Poole,
2013). The tripartite structure consists of an integral membrane
eﬄux transporter with broad substrate specificity (MexB, MexD,
MexF, MexY), an outer membrane channel (OprM, OprJ, OprN,
OprA), and a periplasmic protein adapter (MexA, MexC, MexE,
MexX) (Li et al., 2015). The RND pumps use the proton motive
force to capture antimicrobials from the periplasmic space and
directly to extrude antimicrobials out of the cell (Li et al.,
2015). Among them, the MexXY system is the only significant
determinant of eﬄux-mediated aminoglycoside resistance in
P. aeruginosa (Morita et al., 2012a).
The phenyl-arginine-β-naphthylamide (PAβN, MC-207,110)
is well-known as a non-specific inhibitor against the RND-type
multidrug eﬄux pumps in P. aeruginosa (Lomovskaya et al.,
2001). However it antagonized the anti-pseudomonas activity
of aminoglycosides (amikacin and netilmicin) in a MexXY-
dependent manner even though it inhibited MexXY-dependent
fluoroquinolone (levofloxacin) resistance of P. aeruginosa (Mao
et al., 2001). MP 601384, the only inhibitor of the MexXY-
mediated aminoglycoside resistance has been reported to date
(Jassem et al., 2011) although its chemical structure was not
revealed.
In the current study we identify berberine, a natural
isoquinoline alkaloid produced by a variety of plant species
(Tillhon et al., 2012), potentiates aminoglycoside activity
against P. aeruginosa including multidrug resistant isolates
through screening from traditional Japanese herbal preparations,
frequently prescribed as Kampo prescriptions (Watanabe et al.,
2011). This compound has been reported as a potent eﬄux
inhibitor against Gram-positive bacteria such as Staphylococcus
aureus (Tillhon et al., 2012) but it has a weak activity against
Gram-negative bacteria such as P. aeruginosa in part due to a
substrate of multidrug eﬄux pumps (Tegos et al., 2002).
MATERIALS AND METHODS
Bacterial Strains, Plasmids, and Growth
Conditions
The bacterial strains and plasmids used in this study are listed
in Table 1. Of note various P. aeruginosa strains in which
contribution of the MexXY eﬄux system to aminoglycoside
resistance were assessed before (Morita et al., 2012a) are used
in the main (PAO1; a reference strain, PAGU 1498 and PAGU
1606; multidrug resistant clinical isolates, PAGU 1569; pan-
aminoglycoside clinical isolates) (Table 1). Among the four
strains PAGU 1498 is the agrZ-type MexXY-overproducing
mutant (Morita et al., 2012a).
Bacterial cells were grown (unless otherwise indicated) in
Luria (L) broth and on L agar (1.5%) under aerobic conditions
at 37◦C, as previously described, with antibiotics as specified
(Morita et al., 2015b). Bacterial growth was quantified by
measuring the optical density at 600 nm on an Ultrospec 2100
Pro Spectrophotometer (GE Healthcare Corp., Tokyo, Japan),
unless otherwise indicated. Cells harboring the plasmid pEX18Tc
(Hoang et al., 1998) or derivatives thereof were maintained on
medium supplemented with 2.5–10 µg/ml tetracycline for E. coli
or and selected on medium supplemented with 20–150 µg/ml
tetracycline for P. aeruginosa. Cells harboring the plasmid pFLP2
(Hoang et al., 1998) were maintained and selected on medium
supplemented with 100 µg/ml ampicillin for E. coli or 50–200
µg/ml carbenicillin for P. aeruginosa.
Construction of P. aeruginosa Mutants
In-frame deletionmutants and/or aacC1-gfp insertionmutants of
mexXY,mexZ, andmexVW from P. aeruginosa PAO1 derivatives
were constructed using the previously described sacB-based
strategy (Morita et al., 2006, 2010, 2015a). The plasmids and
resulting P. aeruginosa mutants are listed in Table 1, while the
primer pairs are listed in Table 2. To introduce gene deletions
into strains of P. aeruginosa, deletion constructs were first
prepared in plasmid pEX18Tc by cloning PCR-amplified 0.75-
kb DNA fragments corresponding to the regions upstream
and downstream of the gene sequences to be deleted. The
selection concentrations of tetracycline and gentamicin for the
recombination events were adjusted to reflect the endogenous
tetracycline and gentamicin MICs of the P. aeruginosa strains.
These constructs were confirmed by colony PCR.
Preparation of Crude Drug Extracts
A total of 96 crude drugs (listed in Table S1) that are used in
Kampo prescriptions in Japan (Tanabe et al., 2014) were prepared
as follows. Ten grams of each crude drug was placed into 100
ml of methanol and extracted for 1 day at room temperature,
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TABLE 1 | Bacterial strains and plasmids.
Strain names Other strain names Relevant characteristics Reference or Source
E. COLI
PAGUg0121 DH5α For recombinant DNA manipulation Morita et al., 2010
PAGUg0856 S17-1 For conjugational transfer Morita et al., 2006
P. AERUGINOSA
PAGU 0974 K767, PAO1 PAO1 (Poole Lab), wild type Morita et al., 2006
PAGUg0975 K1525 K767 1mexXY Sobel et al., 2003
PAGU 1498 PA7 Multidrug-resistant clinical isolate Roy et al., 2010
mexXY-oprA overexpressed Morita et al., 2012a
PAGUg1565 PA7 1mexXY-oprA Morita et al., 2012a
PAGU 1606 NCGM2. S1, IMCJ2.S1 Multidrug-resistant clinical isolate Sekiguchi et al., 2005
PAGUg1659 PAGU 1606 1mexXY Morita et al., 2012a
PAGU 1569 K2162 Pan-aminoglycoside-resistant clinical isolate Sobel et al., 2003
PAGUg1627 K2170 K2162 1mexXY Sobel et al., 2003
PAGU 0847 PAO1 PAO1 (Tsuchiya Lab), wild type Morita et al., 2001a
PAGUg0849 YM34 PAGU 0847 mexAB::FRT, mexCD-oprJ::FRT, mexEF-oprN::FRT Morita et al., 2001b
PAGUg0850 YM44 PAGU 0847 mexAB::FRT, mexCD-oprJ::FRT, mexEF-oprN::FRT, mexXY ::FRT Li et al., 2003
PAGUg1881 YM34 1mexZ This study
PAGUg1927 YM34 1mexZ, mexVW::gfp-aacC1 This study
PAGUg1929 YM34 1mexZ, 1mexVW This study
PAGUg1931 PAGUg1927::1mexXY This study
PAGUg1933 PAGUg1929::1mexXY This study
PAGU 1607 NCGM798, IMCJ798 Multidrug-resistant clinical isolate Kitao et al., 2009
PAGU 1608 NCGM799, IMCJ799 Multidrug-resistant clinical isolate Kitao et al., 2009
PAGU 1640 PA9085CB Multidrug-resistant clinical isolate Dr. Tam’s Gift, (Houston, USA)
PAGU 1675 U33b Multidrug-resistant clinical isolate Bradbury et al., 2010
PAGU 0217 GTC 2017, 10-49 Multidrug-resistant clinical isolate Dr. Sawamura’s Gift (Gifu, Japan)
PAGU 1249 No.514 Multidrug-resistant clinical isolate Tsuchimochi et al., 2008
PAGU 1717 NCGM1179 Multidrug-resistant clinical isolate Tada et al., 2011
OTHER BACTERIA
PAGU 0002T ATCC 27061T Achromobacter xylosoxidans subsp. xylosoxidans Yabuuchi et al., 1998
PAGU 0013T ATCC 25416T Burkholderia cepacia Yabuuchi et al., 1992
PAGU 1567T ATCC 19606T Acinetobacter baumannii Kumar et al., 2010
PLASMIDS
pEX18Tc Hoang et al., 1998
pCSV05-01 pEX18Tc::1mexXY Sobel et al., 2003
pYM021 pEX18Tc::1mexZ Morita et al., 2006
pYM145 pEX18Tc::1mexVW This study
pPS858 Source of aacC1-gfp fragment flanked by FRT sites Hoang et al., 1998
pYM146 pYM145 inserted with aacC1-gfp flanked by FRT sites This study
pFLP2 Flp recombinase plasmid Hoang et al., 1998
TABLE 2 | Primers used in this study.
Primer Sequence (5′–3′) Purpose References
SacI-mexVW-UF GCTAGAGCTCCTGGTAGTGGCCAACGGCG mexVW genes disruption of P. aeruginosa PAO1 derivatives This study
BamHI-mexVW-UR CTGAGGATCCCATAATCCTGGTCCCTGGTATGCC mexVW genes disruption of P. aeruginosa PAO1 derivatives This study
BamHI-mexVW-DF GCATGGATCCTGATCGGAAACGGCGGAC mexVW genes disruption of P. aeruginosa PAO1 derivatives This study
HindIII-mexVW-DR CTAGAAGCTTTGCCGAGGGGCTTGAGGT mexVW genes disruption of P. aeruginosa PAO1 derivatives This study
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and then the solution was filtered. The extraction process was
performed three times. Each filtrate was mixed and concentrated
in vacuo at 40◦C by using a rotary evaporator N-1000 (EYELA,
Tokyo, Japan) equipped with a coolant system CCA-1110
(EYELA, Tokyo, Japan). Each final extract was dissolved in
dimethyl sulfoxide (DMSO) and adjusted to the concentration of
100 mg/ml. Each of the crude drugs was resuspended at 1 mg/ml
in DMSO, and evaluated on the condition of the broth micro-
dilution method described above at the Section of Preparation
of Crude Drug Extracts for the ability to restore effectiveness of
either 16 µg/ml imipenem, 4 µg/ml ciprofloxacin, or 32 µg/ml
amikacin against highly multidrug-resistant P. aeruginosa PAGU
1606.
Antibiotic Susceptibility Assay
The susceptibility of P. aeruginosa to antimicrobial agents
in cation-adjusted Mueller–Hinton broth was assessed
using the two-fold serial micro-titer broth dilution method
described previously (Morita et al., 2012a). Minimal inhibitory
concentrations (MICs) were defined as the lowest concentration
of antibiotic resulting in visible inhibition of growth after about
18–22 h of incubation at 37◦C (for P. aeruginosa) or after about
20–24 h of incubation at 35◦C (for Achromobacter xylosoxidans,
Burkholderia cepacia, and Acinetobacter baumannii). The
categorization as susceptible, intermediate, and resistant was
performed according to the interpretive standards of the Clinical
and Laboratory Standards Institute (CLSI).
The fractional inhibitory concentration (FIC) index was
calculated as reported elsewhere (Lomovskaya et al., 2001). The
effects of the drugs were interpreted to be indicative of synergy
when the index was ≤ 0.5.
Amikacin, ampicillin, azithromycin, berberine, carbenicillin,
ciprofloxacin, erythromycin, gentamicin, lincomycin, and
tetracycline were purchased from Wako Pure Chemicals
Industries, Ltd. (Osaka, Japan). Phenylalanine-arginine β-
naphthylamide was purchased from Sigma-Aldrich Co. LLC
(Tokyo, Japan). Imipenem/cilastatin and cefepime were
purchased from Sandoz K.K. (Tokyo, Japan). Piperacillin was
purchased from Nichi-Iko Pharmaceutical Co., Ltd. (Toyama,
Japan). Tobramycin was purchased from Towa Pharmaceutical
Co., Ltd. (Kadama, Osaka, Japan). Arbekacin was purchased
from Shiono Chemical Co., Ltd. (Fujioka, Gunma, Japan).
High Performance Liquid Chromatographic
Method for Quantification of Berberine and
Coptisine
The stock solutions of berberine and coptisine were both
prepared in methanol. The extracts also were dissolved in
methanol to a concentration of 1 mg/ml. In order to construct
calibration curves, a series of standard solution of each
compound was prepared by appropriate dilution of the stock
solutions. Calibration curves were constructed by plotting the
peak area ratio vs. the concentration.
The high performance liquid chromatographic conditions
were as follows: pump, Hitachi L-2130; autosampler, Hitachi L-
2200; detector, Hitachi L-2455; column, YMC Pack ODS-AP302
(4.6 x 150 mm, YMC); mobile phase, 0.1 M phosphate buffer
(pH 2.1)—methanol (70:30, v/v); flow rate, 1 ml/min; column
temperature, 25◦C; DAD, 340 nm; and injection volume, 10 µl.
Molecular Biology Techniques
Plasmid DNA isolation from E. coli, DNA purification,
measurement of DNA concentration, DNA digestion with
restriction enzymes, DNA dephosphorylation, DNA ligation,
isolation of chromosomal DNA from P. aeruginosa, PCR
conditions, nucleotide sequencing, competent cell preparation
from E. coli, transformation of E. coli, and transfer of plasmids
into P. aeruginosa via conjugation were performed as described
previously (Morita et al., 2015b), unless otherwise indicated.
DNA sequences and amino acid sequences were analyzed using
the Pseudomonas Genome Database (Winsor et al., 2011), Basic
Local Alignment Search Tool (BLAST), and the software DNASIS
Pro (Ver. 2.1; Hitachi, Japan).
RESULTS
Isolation of a Novel Inhibitor of the MexXY
Multidrug Efflux System from the
Rhizomes of Coptis Japonica and the Bark
of Phellodendron Amurense
Extracts from the Coptidis Rhizoma (the rhizomes of Coptis
japonica var. major Satake) or Phellodendri Cortex (the bark
of Phellodendron chinense Schneider) restored the effectiveness
of 32 µg/ml amikacin against the highly multidrug-resistant
P. aeruginosa PAGU 1606. None of the tested extracts restored
susceptibility of the strain to 16 µg/ml imipenem or 4 µg/ml
ciprofloxacin (data not shown). The extracts of both Coptis
rhizome and Phellodendron bark reduced MICs of amikacin and
gentamicin (but not those of imipenem or ciprofloxacin) by
eight-fold or more in the two multidrug resistant P. aeruginosa
strains (PAGU 1606 and PAGU 1498) (Table 3).
Berberine Is a Novel Inhibitor of
Aminoglycoside Resistance Dependent on
the MexXY-Efflux System in P. aeruginosa
Berberine is reported the most abundant benzylisoquinoline
alkaloid in the two active extracts (Tillhon et al., 2012). Therefore,
we next tested the activity of berberine along with coptisine, a
similar benzylisoquinoline alkaloid. Berberine constituted 34.4%
of the extract from the rhizomes of C. japonica and 28.3% of
extract from the bark of Phellodendron amurense (Figure S1).
Coptisine was the second-most abundant benzylisoquinoline
alkaloid from the Coptis extract, constituting 4.1% of the extract
from the rhizomes of C. japonica (Figure S1). Although berberine
was ineffective as a solo antibacterial (with an MIC >512
µg/ml MIC against P. aeruginosa; data not shown), berberine
inhibited aminoglycoside resistance by two- to >eight-fold
against four P. aeruginosa strains (Table 4). Such a reduction
was not observed in isogenic mutants deficient in the RND-type
multidrug eﬄux system MexXY, which is considered one of the
major aminoglycoside resistance determinants in P. aeruginosa
(Morita et al., 2012b) (Table 4). Coptisine showed activity similar
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TABLE 3 | Methanol extracts from the Coptidis Rhizoma restore aminoglaycoside susceptibility in multidrug-resistant P. aeruginosa.
P. aeruginosa Strain Relevant property MIC (µg/ml)*
AMK GEN CIP FEP IPM
− + − + − + − + − +
PAGU 1606 Multidrug resistant 256 32 64 8 64 64 >128 >128 128 128
PAGU 1498 Multidrug resistant 32 4 >512 64 128 64 32 16 1 2
PAO1 (PAGU 0974) Wild type 2 1 2 0.5 0.25 0.25 4 4 0.5 1
AMK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; FEP, cefepime; IPM, imipenem.
*MICs are measured in the absence (−) or presence (+) of methanol extract from the Coptidis Rhizoma.
TABLE 4 | Berberine attenuates aminoglycoside resistance of P. aeruginosa in the MexXY -dependent manner.
Strains Relevant property MIC (µg/ml) with (+) and without (–) addition of 256 µg/ml BB
AMK ABK GEN TOB
− + − + − + − +
PAGU 1606 Multidrug resistant 256 32 32 4 64 16 256 64
PAGUg1659 PAGU 1606 1XY 8 4 1 0.5 1 0.5 16 8
PAGU 1498 Multidrug resistant 32 4 32 4 >512 128 >256 32
PAGUg1565 PAGU 1498 1XY 2 1 2 1 16 8 16 8
PAGU 1569 Pan-AG resistant 256 64 128 16 256 64 32 16
PAGUg1627 PAGU 1569 1XY 32 16 16 16 8 8 4 4
PAGU 0974 Wild type, PAO1 2 1 1 0.5 2 1 0.5 0.25
PAGUg0975 PAGU 0974 1XY 0.5 0.5 0.25 0.25 0.25 0.25 0.25 0.125
AG, aminoglycoside; AMK, amikacin; ABK, arbekacin; BB, berberine; GEN, gentamicin; TOB, tobramycin; XY, mexXY.
to that of berberine (data not shown). These results indicate that
the inhibitory activity of the two extracts reflected, at least in part,
the activity of berberine and/or coptisine. Of note berberine also
inhibited aminoglycoside resistance of A. xylosoxidans PAGU
0002T and B. cepacia PAGU 0013T but not that of A. baumannii
PAGU 1567T (Table 5).
Berberine Inhibits MexXY-Mediated
Resistance to Erythromycin, Lincomycin,
and Cefpirome in a P. aeruginosa Mutant
Lacking Four RND Multidrug Efflux
Systems (MexAB, MexCD, MexEF, and
MexVW)
To test the effect of berberine on non-aminoglycoside
susceptibility, we, first of all, evaluated MICs against the
wild-type strain (PAO1) and then, in order to remove any effects
of the RND pumps, evaluated MICs in a multidrug-sensitive
P. aeruginosa strain mutated in the loci encoding four RND
multidrug eﬄux systems (mexXY, mexAB, mexCD-oprJ, and
mexEF-oprN) (Morita et al., 2001b; Li et al., 2003) (Table 6). Like
the parent strain, the quadruple eﬄuxmutant (PAGUg 0850) also
exhibited an eight-fold decrease in MIC of erythromycin in the
presence of berberine (Table 6). However mutation of one of the
remaining RND multidrug eﬄux systems (mexVW) attenuated
the effect of berberine, with the quintuple mutant (PAGUg
TABLE 5 | Berberine attenuates aminoglycoside resistance of
A. xylosoxidans and B. cepacia.
Strains MIC (µg/ml) with (+) and without (–) addition of 256
µg/ml BB
AMK ABK GEN TOB
– + – + – + – +
A. xylosoxidans
PAGU 0002T
>512 64 >512 64 >512 16 512 16
B. cepacia
PAGU 0013T
256 16 128 16 256 16 256 8
A. baumannii
PAGU 1567T
32 32 32 32 64 64 8 8
AMK, amikacin; ABK, arbekacin; BB, berberine; GEN, gentamicin; TOB, tobramycin.
1933) exhibiting only a two-fold decrease in erythromycin
MIC upon exposure to berberine (Table 6). Similar effects were
seen for lincomycin resistance (Table 6). These results suggest
that berberine attenuation of resistance to the macrolides and
lincomycin depends on the MexVW multidrug eﬄux system.
The molecular mechanism underlying the berberine effects on
the MexVW system will be the subject of further research.
We sought to better understand the molecular mechanism
of berberine attenuation of the MexXY-mediated eﬄux.
Therefore, adjuvant effects of berberine on resistance to various
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TABLE 6 | Berberine inhibits MexXY- or MexVW-mediated resistance of P. aeruginosa mutants.
Strain Relevant property mex gene* present MIC (µg/ml) with (+) and without (–) addition of 256 µg/ml BB
ERY LIN FEP CIP TET
− + − + − + − + − +



























M 8 4 16 8 0.125 0.125 0.008 0.002 0.03 0.008
*mex genes here mean mexAB-oprM, mexCD-oprJ, mexEF-oprN, mexXY, and mexVW.
BB, berberine; ERY, erythromycin; LIN, lincomycin; FEP, cefepime; CIP, ciprofloxacin; TET, tetracycline; ABM, mexAB-oprM; CDJ, mexCD-oprJ; EFN, mexEF-oprN; XY, mexXY; VW,
mexVW; AB, mexAB; M, oprM; nd, not done.
antimicrobial substrates of the MexXY eﬄux pump were
compared in two RND mutant strains differing only by the
absence or presence of mexXY (PAGUg 1929 vs PAGUg 1933,
respectively; Table 6). Specifically, the mexXY genes were
overexpressed in PAGUg 1933 due to deletion of the mexZ
repressor gene. The effects of mexXY overexpression were being
determined in the absence of other major RND multidrug eﬄux
systems, since the two strains shared deletions in the mexAB,
mexCD-oprJ, mexEF-oprN, and mexVW loci. As seen in the
earlier experiments (e.g., Table 6), resistance to erythromycin,
lincomycin, cefpirome, and aminoglycosides was attenuated
eight-fold in the presence of berberine, and these effects were
observed only in the presence of the MexXY system (Table 6).
While resistance to ciprofloxacin and tetracycline also was
attenuated eight-fold in the presence of berberine, a partial
berberine effect (four-fold decrease in MIC) was observed for
ciprofloxacin and tetracycline even in the absence of mexXY
overexpression (compare PAGUg 1929 and PAGUg 1933;
Table 6). It might suggest that berberine possibly has another
target sites other than 5 RND pumps which are involved
in resistance to ciprofloxacin and tetracycline. In control
experiments (data not shown), we confirmed that berberine
did not display antimicrobial activity (at concentrations up to
512 µg/ml) in the PAGUg 1929 strain (that is, despite deletion
of mexAB, mexCD-oprJ, mexEF-oprN, and mexVW). We
additionally confirmed that the attenuation activity of berberine
in the PAGUg 1929 background was still concentration-
dependent; the aminoglycoside adjuvant activity of berberine in
this strain was not detected at a berberine concentration of 8
µg/ml (data not shown).
Comparison of Berberine with the Known
Efflux Inhibitor Phenylalanine-Arginine
β-Naphthylamide (PAβN)
We compared the effects of berberine with those of the previously
reported eﬄux inhibitor PAβN. Consistent with earlier reports
(Mao et al., 2001), PAβN did not reduce MexXY-dependent
gentamicin resistance (as seen in PAGUg 1929), but PAβN did
inhibit ciprofloxacin resistance in the quadruple eﬄux mutant
(mexAB, mexCD-oprJ, mexEF-oprN, and mexVW; PAGUg 1929)
(Table 7). This distinction suggests that berberine inhibits the
MexXY system via a mechanism distinct from that of PAβN.
Given that berberine is known to be substrates of many
multidrug eﬄux pumps, including RND-type multidrug eﬄux
pumps (Tegos et al., 2002), PAβN is expected to facilitate
accumulation of berberine in P. aeruginosa cells. Indeed,
exposure to PAβN provided inhibition of MexXY-dependent
aminoglycoside resistance at a lower concentration of berberine,




Resistance in P. aeruginosa
FIC indices were determined in multiple strains for the
combination of gentamicin and berberine (Table 8). The
combination exhibited synergy only in MexXY-positive strains
(PAGUg1927 and PAGUg1929). This result suggests that
berberine and gentamicin act synergistically on the MexXY
system. Puzzlingly, berberineMICs in the presence of gentamicin
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are significantly higher in the MexXY-deficient P. aeruginosa
mutant cells than in the MexXY-overproducing P. aeruginosa
mutant cells (Table 8). This observation implies that berberine
accumulates more effectively in the presence of the MexXY
system, although classically the pump facilitates the eﬄux of
substrates.
Berberine Promotes Combined Effects of
Amikacin with Piperacillin (and Vice Versa)
in Multidrug-Resistant P. aeruginosa
Strains
Aminoglycoside uptake is known to be facilitated by inhibitors
of bacterial cell wall synthesis such as β-lactams (Taber et al.,
1987). Anti-pseudomonal β-lactams and polymyxins thus are
expected to promote the adjuvant effects of berberine observed
above. We tested several such agents (data not shown) and found
that piperacillin, an anti-pseudomonal β-lactam, was among the
most potent. The effects of this cell wall inhibitor were seen in all
TABLE 7 | PAβN inhibits MexXY-mediated resistance to ciprofloxacin but





MIC (µg/ml) with (+) and
without (–) addition of
PAβN**
GEN CIP PAβN













M 0.25 0.25 0.0078 0.0039 32
*mex genes here mean mexAB-oprM, mexCD-oprJ, mexEF-oprN, mexXY, and mexVW.
**Concentrations of PAβN are 1/8-fold MICs for PAβN of PAGUg1929 and PAGUg1933,
respectively.
GEN, gentamicin; CIP, ciprofloxacin; PAβN, phenylalanine-arginine β-naphthylamide;
ABM, mexAB-oprM; CDJ, mexCD-oprJ; EFN, mexEF-oprN; XY, mexXY; VW, mexVW; AB,
mexAB; M, oprM.
of the tested multidrug-resistant P. aeruginosa strains (Table 9).
Notably, exposure to the combination of piperacillin (32 µg/ml)
and berberine (512 µg/ml) reduced the amikacin MIC of PAGU
1606 to a level below the amikacin breakpoint of 32 µg/ml
(Table 9). In contrast, exposure to piperacillin or berberine alone
did not have as large an effect in reducing amikacin resistance.
We additionally noted a reduction in the MIC of piperacillin in
PAGU 1606 when grown in the presence of both of berberine
(512 µg/ml) and sub-breakpoint amikacin (16 µg/ml), with
the piperacillin MIC reduced to a level similar to that seen
when grown in the presence of 128 µg/ml of amikacin alone
(Table 9). Indeed, the FIC index of amikacin in combination
with piperacillin of PAGU 1606 was calculated as follows:
amikacin MIC in the presence of piperacillin/amikacin MIC) +
(piperacillin MIC in the presence of amikacin/piperacillin MIC)
= 64/256+16/256<0.5. It suggested synergy of these two
compounds in PAGU 1606 (Table 9).
DISCUSSION
The MexXY multidrug eﬄux system is a significant determinant
of resistance to aminoglycosides in P. aeruginosa, although
aminoglycosides are not standard RND pump substrates (Morita
et al., 2012b). The MexXY pump typically is encoded by
a two-gene operon and comprises a periplasmic membrane
fusion protein (MexX) and an inner-membrane (IM) drug/H+
antiporter (MexY; the RND component); the pump is functional
only when combined with an outer-membrane (OM) channel
encoded by a separate locus (e.g., OprM, which is encoded by
the third gene of another multidrug eﬄux operon, mexAB-oprM
Morita et al., 2012b). In some P. aeruginosa strains, such as the
taxonomic outlier strain PA7, the mexXY genes are adjacent to a
third gene (oprA in PA7) encoding an outer membrane channel;
the resulting three-gene operon is similar to axyXY-oprZ of A.
xylosoxidans and amrAB-oprA of various Burkholderia species
(e.g., B. pseudomallei and B. cepacia complexes) (Morita et al.,
2012a,b). In the PA7-related strains, MexXY seem to cooperate
with both OprM and OprA, as either of these Opr proteins can
compensate for the genetically engineered suppression of the
other (Morita et al., 2012b; Li et al., 2015). In P. aeruginosa,
the MexXY system mediates resistance to aminoglycosides
as well as various clinically relevant antimicrobials such as
fluoroquinolones, some β-lactams (e.g., cefepime), tetracyclines
TABLE 8 | Berberine synergistically inhibits MexXY-mediated gentamicin resistance in P. aeruginosa mutants.
Strain XY AAC MIC (µg/ml) for GEN in the presence of: MIC (µg/ml) for BB in the presence of: FIC Mode of Interaction
− +BB − +GEN
PAGUg1927 + + 1024 256 >512 128 <0.5 Synergy
PAGUg1931 − + 8 16 >512 >512 >2.0 Indifferent
PAGUg1929 + − 8 2 >512 128 <0.5 Synergy
PAGUg1933 − − 0.25 0.25 >512 >512 >1.0 Indifferent
GEN, gentamicin; BB, berberine; XY, mexXY; AAC, aacC1*.
*aacC1 is a gentamycin acetyl transferase-encoding gene derived from pPS858 (Hoang et al., 1998).
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TABLE 9 | Berberine enhances synergistic effect of piperacillin and amikacin (and vice versa) in multidrug-resistant P. aeruginosa strains.
Strain AMK MIC (µg/ml) in the presence of: PIPC MIC (µg/ml) in the presence of:
− BB (512) PIPC (32) BB (512) PIPC (32) − BB (512) AMK (128) BB (512) AMK (16)
PAGU 1606 256 64 64 16 256 256 16 32
PAGU 1607 256 nd nd 16 256 nd nd 32
PAGU 1608 256 nd nd 16 256 nd nd 32
PAGU 1640 64 nd nd 16 1024 nd nd 64
PAGU 1675 >1024 nd nd 64 1024 nd nd 256
PAGU 0217 256 nd nd 8 256 nd nd 32
PAGU 1249 >1024 nd nd 4 256 nd nd <0.5
PAGU 1717 128 nd nd 2 128 nd nd 8
AMK, amikacin; BB, berberine, PIPC, piperacillin; nd, not done.
Values in parentheses are concentrations (µg/ml) of indicated drugs.
(including tigecycline), and macrolides such as azithromycin
(Morita et al., 2012b). In wild-type cells, the mexXY operon is
induced by agents that target ribosomes (Jeannot et al., 2005;
Morita et al., 2006); the operon is overexpressed in mutant
cells (e.g., Morita et al., 2012b; Guénard et al., 2014). Potent
inhibitors of RND-type eﬄux pumps could be used as adjunctive
therapies that would increase the potency of existing antibiotics
and decrease the emergence of multidrug resistance in Gram-
negative pathogens such as P. aeruginosa and Enterobacteriaceae
(Gill et al., 2015; Opperman and Nguyen, 2015; Venter et al.,
2015). Several potent inhibitors of RND-type eﬄux pump (e.g.,
PAβN (Lomovskaya et al., 2001), D13-9001 (Nakashima et al.,
2013), and MBX2319 Vargiu et al., 2014) have been reported.
However, only a single inhibitor ofMexXY (MP 601384) has been
reported to date (Jassem et al., 2011); the chemical structure of
that agent was not revealed.
In the present study, berberine was shown to synergistically
inhibit aminoglycoside resistance in P. aeruginosa in a
MexXY-dependent manner. We observed a similar effect in A.
xylosoxidans and B. cepacia, distinct species that possess MexXY
orthologues (Morita et al., 2012b). On the other hand, we did
not observe berberine attenuation of aminoglycoside resistance
in A. baumannii. In Acinetobacter, the AdeAB RND-type pump
mediates aminoglycoside resistance (Magnet et al., 2001), and the
AdeAB system exhibits more sequence similarity to P. aeruginosa
MexCD than to P. aeruginosa MexXY (Morita et al., 2012b).
Furthermore, berberine attenuated MexXY-dependent resistance
to aminoglycosides in a P. aeruginosa harboring MexXY but
lacking another four RNDmultidrug eﬄux systems.We observed
the same effect in this background for antimicrobials of other
classes (including erythromycin, cefepime, and lincomycin) that
are considered substrates of the MexXY pump (Morita et al.,
2012b). Berberine is a natural isoquinoline alkaloid produced by
a variety of plant species; this compound has been reported to
possess a number of biological activities, including antimicrobial
effects (Tillhon et al., 2012). Recently, berberine’s antibacterial
properties were shown to be due primarily to inhibition of the
cell division protein FtsZ (Domadia et al., 2008; Boberek et al.,
2010). However, this compound’s antibacterial activity is not
strong against Gram-negative bacteria such as P. aeruginosa at
least in part because many bacterial multidrug eﬄux pumps
recognize berberine as a substrate (e.g., Morita et al., 1998; Tegos
et al., 2002). Berberine is more potent against Gram-positive
bacteria such as Mycobacterium tuberculosis and S. aureus
by inhibiting MF-type multidrug eﬄux pumps such as NorA
(Tegos et al., 2002). The MexXY system confers berberine
resistance in Escherichia coli lacking the major RND-type
mulidrug eﬄux system AcrAB (data not shown) as well as
confers PAβN resistance in P. aeruginosa lacking the major RND
pumps (Table 6), suggesting that each of the two agents acts as
a competitive inhibitor of substrate binding and/or extrusion.
However each spectrum of antimicrobial potentiation is not the
same. Unfortunately, the adjuvant activity of berberine requires
(in Pseudomonas) a relatively high (>100µg/ml) concentration
of the compound, consistent with a limited ability to inhibit the
MexXY eﬄux. Clinical development would require optimization
of the structure of berberine to provide better synergistic activity
with aminoglycosides against P. aeruginosa. Recently a region of
MexY (the substrate-specificity-determining RND component
of this pump) that corresponds to a proximal binding pocket of
AcrB was shown to be involved in aminoglycoside recognition
and eﬄux (Lau et al., 2014; Li et al., 2015). This protein domain
would be a good starting place for understanding details of
aminoglycoside recognition and export by MexY. Although
the substrate specificity of E. coli AcrAB-TolC (the best studied
RND-type multidrug eﬄux pump) is extraordinarily broad,
the complex does not recognize aminoglycosides as substrates
(Li et al., 2015). The design and development of better MexXY
inhibitors will require improved understanding of the molecular
mechanisms of MexXY-mediated aminoglycoside resistance.
In conclusion berberine is the first eﬄux inhibitor that restores
aminoglycosides activity in multidrug resistant P. aeruginosa. As
aminoglycosides are molecules of choice to treat severe infections
the clinical impact is potentially important.
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